BVS
Bioventus Inc.
$8.51
-1.96%
$710.9M
No data for this timeframe.
Vol
Market Cap$710.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders50 funds
Inst. Value$138.4M
Inst. Activity7 buys / 3 sells
Insider Activity0B / 1S
Insider Net $-$105.4K
SEC Reports9
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001665988·Prev Close $8.68
Recent Activity
Jun 11, 2026
SEC
Three institutional sellers outnumber one buyer in Bioventus during Q3 2025, with a net reduction of approximately $1.9M
INST-CLUSTER — Impact 4/10
Jun 3, 2026
Insider
NEELS GUIDO J was granted 25,146 shares
Director
Jun 3, 2026
Insider
Beyer Pat was granted 25,146 shares
Director
Jun 3, 2026
Insider
Ladone Mary Kay was granted 25,146 shares
Director
Jun 2, 2026
SEC
Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue of $155.4M (in line w
PRESS-RELEASE — Impact 6/10
May 21, 2026
SEC
Bioventus disclosed that the FDA reclassified its Exogen Ultrasound Bone Healing System from Class III to Class II, and
8-K — Impact 3/10
Inst.
SEI INVESTMENTS CO — DOUBLED
289,648 shares ($2.6M)
Inst.
Trexquant Investment LP — ADD
240,372 shares ($2.2M)
Price Targets
$14.80
+73.9% upside
Strong Buy
Current $8.51
Low $14.00
Median $15.00
High $16.00
5 analysts
$14.00
$16.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 6, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 6, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
| Feb 9, 2026 | Barrington Research | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.22 ▼ -8.1% | $0.20 — $0.23 | 3% YoY | 5 |
| Next Q | $0.18 ▼ -7.4% | $0.16 — $0.19 | 17% YoY | 5 |
| Current FY | $0.78 ▲ +3.5% | $0.77 — $0.78 | 14% YoY | 5 |
| Next FY | $0.91 ▲ +4.1% | $0.87 — $0.97 | 17% YoY | 5 |
Latest Reports
BEARISH
INST-CLUSTER
4/10
Three institutional sellers outnumber one buyer in Bioventus during Q3 2025, with a net reduction of approximately $1.9M
Jun 11, 2026
BEARISH
PRESS-RELEASE
6/10
Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue of $155.4M (in line w
Jun 2, 2026
BULLISH
Press
8/10
Bioventus reported strong Q4 and full-year 2025 results with 10.0% organic revenue growth in Q4, GAAP profitability impr
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $28.6M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.7M | — |
| ROYCE & ASSOCIATES LP | $14.1M | — |
| STATE STREET CORP | $9.0M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $8.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | NEELS GUIDO | A | $0.00 |
| Jun 3, 2026 | Beyer Pat | A | $0.00 |
| Jun 3, 2026 | Ladone Mary | A | $0.00 |
| Jun 3, 2026 | HAWKINS WILLIAM | A | $0.00 |
| Jun 3, 2026 | Cowdy Philip | A | $0.00 |
50 institutional holders with $138.4M total value (15,162,963 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, ROYCE. Net buying activity: 7 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3,133,541 | $28.6M | 20.7% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,714,707 | $15.7M | 11.3% | — |
| 3 | ROYCE & ASSOCIATES LP | 1,541,282 | $14.1M | 10.2% | — |
| 4 | STATE STREET CORP | 988,367 | $9.0M | 6.5% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 973,004 | $8.9M | 6.4% | — |
| 6 | DIMENSIONAL FUND ADVISORS LP | 873,138 | $8.0M | 5.8% | ADD +28.8% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 489,460 | $4.5M | 3.2% | ADD +42.9% |
| 8 | GOLDMAN SACHS GROUP INC | 473,384 | $4.3M | 3.1% | — |
| 9 | FMR LLC | 396,233 | $3.6M | 2.6% | ADD +25.3% |
| 10 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 373,942 | $3.4M | 2.5% | — |
| 11 | VANGUARD FIDUCIARY TRUST CO | 320,973 | $2.9M | 2.1% | — |
| 12 | D. E. Shaw & Co., Inc. | 310,610 | $2.8M | 2.0% | ADD +89.7% |
| 13 | LAZARD ASSET MANAGEMENT LLC | 305,517 | $2.8M | 2.0% | DOUBLED +101.7% |
| 14 | SEI INVESTMENTS CO | 289,648 | $2.6M | 1.9% | DOUBLED +160.7% |
| 15 | TWO SIGMA INVESTMENTS, LP | 259,060 | $2.4M | 1.7% | ADD +31.1% |
| 16 | MORGAN STANLEY | 258,801 | $2.4M | 1.7% | TRIM -62.7% |
| 17 | Trexquant Investment LP | 240,372 | $2.2M | 1.6% | ADD +82.3% |
| 18 | PRUDENTIAL FINANCIAL INC | 193,800 | $1.8M | 1.3% | — |
| 19 | FIFTH THIRD BANCORP | 161,926 | $1.5M | 1.1% | — |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 154,141 | $1.4M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| SEI INVESTMENTS CO | DOUBLED | 111,109 | 289,648 | +160.7% | $2.6M | 2026-Q1 |
| Trexquant Investment LP | ADD | 131,848 | 240,372 | +82.3% | $2.2M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | TRIM | 178,064 | 130,317 | -26.8% | $1.2M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 288,900 | 103,528 | -64.2% | $945.2K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 61,334 | 86,057 | +40.3% | $785.7K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 25,138 | 37,156 | +47.8% | $339.2K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 18,667 | 27,797 | +48.9% | $253.8K | 2026-Q1 |
| HRT FINANCIAL LP | ADD | 130,649 | 203,645 | +55.9% | $1.9K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | NEAR_EXIT | 67,968 | 70 | -99.9% | $639.00 | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 24,648 | 36,811 | +49.3% | $337.00 | 2026-Q1 |
| FMR LLC | ADD | 292,534 | 366,686 | +25.3% | $2.7M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | ADD | 188,892 | 358,257 | +89.7% | $2.7M | 2025-Q4 |
| LAZARD ASSET MANAGEMENT LLC | DOUBLED | 134,121 | 270,509 | +101.7% | $2.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 205,026 | 268,833 | +31.1% | $2.0M | 2025-Q4 |
| PANAGORA ASSET MANAGEMENT INC | TRIM | 325,199 | 178,064 | -45.2% | $1.3M | 2025-Q4 |
| Trexquant Investment LP | DOUBLED | 26,483 | 131,848 | +397.9% | $980.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 32,390 | 61,334 | +89.4% | $456.3K | 2025-Q4 |
| FRANKLIN RESOURCES INC | TRIM | 101,786 | 55,133 | -45.8% | $410.2K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 29,070 | 50,634 | +74.2% | $376.7K | 2025-Q4 |
| Invesco Ltd. | ADD | 21,982 | 33,621 | +52.9% | $250.1K | 2025-Q4 |
| Corient Private Wealth LLC | ADD | 13,440 | 19,471 | +44.9% | $144.9K | 2025-Q4 |
| Allworth Financial LP | ADD | 218 | 276 | +26.6% | $2.1K | 2025-Q4 |
| CWM, LLC | ADD | 4,379 | 5,584 | +27.5% | $42.00 | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 211,695 | 287,619 | +35.9% | $1.9M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 652,911 | 243,749 | -62.7% | $1.6M | 2025-Q3 |
14 unique insiders with 50 transactions. Net insider value: -$105.4K ($0.00 bought, $105.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | NEELS GUIDO J | Director | AWARD | 25,146 | — | — |
| Jun 3, 2026 | Beyer Pat | Director | AWARD | 25,146 | — | — |
| Jun 3, 2026 | Ladone Mary Kay | Director | AWARD | 25,146 | — | — |
| Jun 3, 2026 | HAWKINS WILLIAM A | Director | AWARD | 30,994 | — | — |
| Jun 3, 2026 | Cowdy Philip G. | Director | AWARD | 25,146 | — | — |
| Jun 3, 2026 | STALNECKER SUSAN M | Director | AWARD | 25,146 | — | — |
| Jun 3, 2026 | McMurry-Heath Michelle | Director | AWARD | 25,146 | — | — |
| Jun 3, 2026 | SUTTER MARTIN P | Director | AWARD | 25,146 | — | — |
| Jun 3, 2026 | NOHRA GUY P | Director | AWARD | 25,146 | — | — |
| Jun 3, 2026 | Bartholdson John A. | Director | AWARD | 25,146 | — | — |
| Jun 2, 2026 | Beyer Pat | Director | EXERCISE | 32,282 | — | — |
| Jun 2, 2026 | Ladone Mary Kay | Director | EXERCISE | 32,282 | — | — |
| Jun 2, 2026 | HAWKINS WILLIAM A | Director | EXERCISE | 39,789 | — | — |
| Jun 2, 2026 | Cowdy Philip G. | Director | EXERCISE | 32,282 | — | — |
| Jun 2, 2026 | NEELS GUIDO J | Director | EXERCISE | 32,282 | — | — |
| Jun 2, 2026 | McMurry-Heath Michelle | Director | EXERCISE | 32,282 | — | — |
| Jun 2, 2026 | NOHRA GUY P | Director | EXERCISE | 32,282 | — | — |
| Jun 2, 2026 | STALNECKER SUSAN M | Director | EXERCISE | 32,282 | — | — |
| Jun 2, 2026 | SUTTER MARTIN P | Director | EXERCISE | 32,282 | — | — |
| Jun 2, 2026 | Bartholdson John A. | Director | EXERCISE | 32,282 | — | — |
| Apr 10, 2026 | D'Adamio Anthony | SVP & General Counsel | EXERCISE | 9,925 | — | — |
| Apr 10, 2026 | D'Adamio Anthony | SVP & General Counsel | TAX W/H | 4,312 | $9.06 | $39.1K |
| Apr 10, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | EXERCISE | 4,300 | — | — |
| Apr 10, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | TAX W/H | 1,868 | $9.06 | $16.9K |
| Apr 10, 2026 | Singleton Mark Leonard | SVP & CFO | EXERCISE | 13,000 | — | — |
| Apr 10, 2026 | Singleton Mark Leonard | SVP & CFO | TAX W/H | 5,648 | $9.06 | $51.2K |
| Mar 20, 2026 | Singleton Mark Leonard | SVP & CFO | EXERCISE | 18,625 | — | — |
| Mar 20, 2026 | Singleton Mark Leonard | SVP & CFO | TAX W/H | 8,091 | $8.64 | $69.9K |
| Mar 13, 2026 | Claypoole Robert E | President and CEO | EXERCISE | 33,500 | — | — |
| Mar 13, 2026 | D'Adamio Anthony | SVP & General Counsel | TAX W/H | 3,861 | $8.62 | $33.3K |
| Mar 13, 2026 | D'Adamio Anthony | SVP & General Counsel | AWARD | 83,000 | — | — |
| Mar 13, 2026 | D'Adamio Anthony | SVP & General Counsel | AWARD | 92,000 | — | — |
| Mar 13, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | AWARD | 24,000 | — | — |
| Mar 13, 2026 | Singleton Mark Leonard | SVP & CFO | AWARD | 116,000 | — | — |
| Mar 13, 2026 | Singleton Mark Leonard | SVP & CFO | AWARD | 104,000 | — | — |
| Mar 13, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | EXERCISE | 3,455 | — | — |
| Mar 13, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | TAX W/H | 1,501 | $8.62 | $12.9K |
| Mar 13, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | AWARD | 27,000 | — | — |
| Mar 13, 2026 | Claypoole Robert E | President and CEO | TAX W/H | 14,553 | $8.62 | $125.4K |
| Mar 13, 2026 | Claypoole Robert E | President and CEO | AWARD | 278,000 | — | — |
| Mar 13, 2026 | Claypoole Robert E | President and CEO | AWARD | 309,000 | — | — |
| Mar 13, 2026 | Singleton Mark Leonard | SVP & CFO | TAX W/H | 5,865 | $8.62 | $50.6K |
| Mar 13, 2026 | Singleton Mark Leonard | SVP & CFO | EXERCISE | 13,500 | — | — |
| Mar 13, 2026 | D'Adamio Anthony | SVP & General Counsel | EXERCISE | 8,886 | — | — |
| Mar 11, 2026 | McMurry-Heath Michelle | Director | SELL | 12,000 | $8.79 | $105.4K |
| Mar 14, 2025 | CHURCH KATRINA J | SVP & Chief Compliance Officer | AWARD | 14,000 | — | — |
| Mar 14, 2025 | D'Adamio Anthony | SVP & General Counsel | AWARD | 40,000 | — | — |
| Mar 14, 2025 | Claypoole Robert E | President and CEO | AWARD | 134,000 | — | — |
| Mar 14, 2025 | D'Adamio Anthony | SVP & General Counsel | AWARD | 35,000 | — | — |
| Mar 14, 2025 | CHURCH KATRINA J | SVP & Chief Compliance Officer | AWARD | 16,000 | — | — |
9 SEC filing reports analyzed. Sentiment: 4 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 5.0/10.
BEARISH
INST-CLUSTER
4/10
Three institutional sellers outnumber one buyer in Bioventus during Q3 2025, with a net reduction of
Jun 11, 2026
BEARISH
PRESS-RELEASE
6/10
Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue o
Jun 2, 2026
NEUTRAL
8-K
3/10
Bioventus disclosed that the FDA reclassified its Exogen Ultrasound Bone Healing System from Class I
May 21, 2026
BULLISH
COURT-RULING
5/10
A derivative shareholder lawsuit against Bioventus and its directors/officers was dismissed without
May 9, 2026
BULLISH
8-K
7/10
Bioventus reported Q1 2026 revenue of $132.1M (+6.6% YoY) and GAAP EPS of $0.04, improving from a -$
May 6, 2026
BULLISH
PRESS-RELEASE
8/10
Bioventus reported Q1 2026 revenue of $132.1M (+7% YoY) and GAAP EPS of $0.04, swinging from a -$0.0
May 6, 2026
NEUTRAL
PRESS-RELEASE
2/10
Bioventus announces Q1 2026 earnings release date for May 6, 2026, before market open. No financial
Apr 28, 2026
NEUTRAL
DEFA14A
2/10
Bioventus Inc. has filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting
Apr 22, 2026
BULLISH
8-K
8/10
Bioventus reported strong Q4 2025 results with $157.9M revenue (2.8% YoY growth, 10% organic growth)
Mar 5, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.80 mean target
+73.9% upside
Strong Buy (3.00)
$14.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $8.51 |
| Target Low | $14.00 |
| Target Mean | $14.80 |
| Target Median | $15.00 |
| Target High | $16.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.22 | $0.20 | $0.23 | 2.9% | -8.1% | 0↑ 3↓ | $0.2B | 5.3% | 5 |
| Next Q 2026-09-30 |
$0.18 | $0.16 | $0.19 | 17.3% | -7.4% | 0↑ 1↓ | $0.1B | 7.3% | 5 |
| Current FY 2026-12-31 |
$0.78 | $0.77 | $0.78 | 14.1% | +3.5% | 3↑ 0↓ | $0.6B | 6.6% | 5 |
| Next FY 2027-12-31 |
$0.91 | $0.87 | $0.97 | 16.8% | +4.1% | 5↑ 0↓ | $0.6B | 6.6% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.216 | |
| 7d ago | $0.217 | -0.002 |
| 30d ago | $0.235 | -0.019 |
| 60d ago | $0.225 | -0.009 |
| 90d ago | $0.237 | -0.021 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 6, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 6, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | Barrington Research | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 1 | 5 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 1 | 5 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
earnings
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
<p>DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PPAKoAaQQUXQ4omwkdMUUxPpd-cDI0k_dPWypqL4rim3_
May 8, 2026
Enforcement
Jung Jae Hyung, Derivatively on Behalf of Bioventus Inc. v. Kenneth M. Reali, Mark L. Singleton, Gregory O. Anglum, Susan M. Stalnecker, William A. Hawkins, III, John A. Bartholdson, Patrick J. Beyer, Phillip G. Cowdy, Mary Kay Ladone, Michelle McMurray-Heath, Guido J. Neels, Guy P. Nohra, David J. Parker, Martin P. Sutter, and Stavros G. Vizirgiankis
Court ruling from District Court, D. Delaware. Docket: 1:25-cv-00806
May 6, 2026
earnings
Bioventus Reports First Quarter Financial Results
<p>DURHAM, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for ac
May 6, 2026
earnings_calendar
BVS Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
earnings_calendar
BVS Q1 2026 Earnings Scheduled — 2026-05-04
Apr 28, 2026
earnings
Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
<p>DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7o-JozEPP_clolmsGGN9mXLP7rdp0pfzm_oxgrDaMBB
Mar 5, 2026
earnings
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
<p><br>DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations
Mar 5, 2026
earnings_calendar
BVS Q4 2025 Earnings After Market Close — 2026-03-05